A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6).

drug protocol number
KYV101-006
drug sponsor
Kyverna Therapeutics, Inc. / Balsam
drug study
KYV101
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase